ATPase

Myosin-IN-2 is a potent Myosin ATPase inhibitor, demonstrating an IC50 of 1.06 μM. This compound plays a critical role in research focused on heart diseases, particularly hypertrophic cardiomyopathy (HCM). By selectively inhibiting Myosin ATPase activity, Myosin-IN-2 provides valuable insights into the mechanisms underlying cardiac function and related pathological conditions.

Azeloprazole is a proton pump inhibitor that targets the H+,K+-ATPase enzyme, effectively reducing gastric acid secretion. It has demonstrated significant efficacy in preclinical models, including a dog's gastric fistula, where it outperformed esomeprazole in terms of duration of action. This compound is useful in studying acid-related diseases and exploring mechanisms of gastric acid regulation.